Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to join the case by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data, claiming superior clinical benefits of SLK over competitors, which was not substantiated [6][7]. - The company's assertions about SLK's Nanobody structure being beneficial compared to traditional monoclonal antibodies are also called into question [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [8].

Core Viewpoint - RCI Hospitality Holdings, Inc. is facing a class action lawsuit due to allegations of tax fraud and bribery, which resulted in misleading statements about the company's business and legal risks [1][2]. Summary by Sections Allegations - The lawsuit claims that during the class period from December 15, 2021, to September 16, 2025, the defendants engaged in tax fraud and bribery to conceal this fraud [1]. - It is alleged that the defendants understated the legal risks facing the company, leading to materially false and misleading statements regarding its business operations and prospects [1]. Class Action Details - Shareholders who purchased RCI Hospitality shares during the specified class period are encouraged to register for the class action, with a deadline set for November 20, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Primo Brands To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities: (a) the common stock of Primo Water between June 17, 2024 through November 8, 2024, inclusive, and/or (b) the common stock of Primo Brands between November 11, 2024 through November 6, 2025, inclusive (collectively, the "Class Period") and would like to discuss your legal rights, call Faruqi & ...

Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK--(BUSINESS WIRE)--Faruqi & Fa ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment between May 20, 2025, and August 18, 2025 [5][2]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in James Hardie to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against James Hardie, with a deadline of December 23, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose the true state of demand in their key segment [5]. Group 2: Financial Impact - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [5]. - Following the announcement of these financial results, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who purchased or sold Cepton common stock between July 29, 2024, and January 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations during the Class Period [5] - Specific claims include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] - The Board of Directors allegedly failed to explore this offer meaningfully, depriving shareholders of the opportunity to consider the acquisition [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quanex Building Products Corporation due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Group 1: Allegations Against Quanex - The complaint alleges that Quanex and its executives made false or misleading statements regarding the maintenance of tooling and equipment at its Tyman Mexico facility, which were significantly underinvested [3]. - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [3]. - The complaint also states that Quanex had previously identified these issues, and the positive statements made by the defendants about the company's operations were materially misleading [3]. Group 2: Financial Impact - On September 4, 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the same period the previous year, and an adjusted EBITDA of $70.30 [4]. - The company disclosed ongoing operational issues related to the Tyman business that impacted results more than expected during the third quarter of 2025 [4]. - During an earnings call on September 5, 2025, CEO George Wilson noted that operational challenges negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone [5]. Group 3: Stock Price Reaction - Following the announcement of the financial results and operational issues, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025, with unusually heavy trading volume [5]. - The stock continued to decline, falling by $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025, also on unusually heavy trading volume [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. for allegedly misleading investors regarding the company's competitive position and financial performance during the class period from March 5, 2024, to October 28, 2025 [1][3]. Group 1: Allegations Against Avantor - The complaint alleges that Avantor and its executives violated federal securities laws by making false and misleading statements about the company's competitive positioning and failing to disclose the negative impacts of increased competition [3]. - Defendants misled investors by downplaying the effects of competition, claiming that Avantor's lab business was performing well and that the company had strong competitive advantages [4]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the resignation of CEO Michael Stubblefield, leading to a stock price decline of $2.57 (over 16.5%) from $15.50 to $12.93 [5]. - The company continued to report weak financial results, including a year-over-year decrease in net sales and a further reduction in guidance, resulting in a stock price drop of $2.08 (over 15%) from $13.44 to $11.36 on August 1, 2025 [6]. - On October 29, 2025, Avantor reported a net loss of $712 million and -5% organic revenue growth, leading to a significant stock price decline of $3.50 (over 23%) from $15.08 to $11.58 [7][8].

If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) and reminds investors of ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Stride, Inc. for the period between October 22, 2024, and October 28, 2025, due to misleading statements and omissions regarding the company's products and services [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Stride, Inc. made misleading statements about its products and services aimed at public and private schools, which included inflated enrollment numbers and non-compliance with statutory requirements [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Stride, Inc. securities during the class period [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 12, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].